Atossa Therapeutics rises as Canada permits phase 2 of cancer drug trial

Atossa Therapeutics

20/07/2023 20:49

** Shares of drug developer Atossa Therapeutics  ATOS.O 
jump 6.5% to $1.14 after the bell
    ** Company says Health Canada issued a "No Objection Letter"
for phase 2 clinical trial of its drug Evangeline for
pre-menopausal women with breast cancer 
    ** Says it can now open sites and enroll patients for the
second phase of the study throughout Canada
    ** As of last close, stock had more than doubled YTD 
    

 (Reporting by Savyata Mishra in Bengaluru)
 ((Savyata.Mishra@thomsonreuters.com))